Global Oncolytic Virus Therapies Market - 1-3 USERS:2021

Market Report Coverage :
Start Year : 2020 - Forecast Year : 2030 - Start Value : $93.3 Million in 2020 - Forecast Value : $962.0 Million by 2030 - CAGR % : 0.26%
Description :
Market Report Coverage - Oncolytic Virus TherapiesMarket Segmentation• Commercialized Therapies: Imlygic, Oncorine, and RIGVIR• Pipeline Therapies: Phase I, Phase II, Phase III, Phase IV• Type of Virus: Genetically Engineered Oncolytic Viruses (Herpes Simplex Virus, Adenovirus, and Vaccinia Virus), Oncolytic Wild-Type Viruses (Reovirus, Newcastle Disease Virus, and Vesicular Stomatitis Virus)• Application: Solid Tumors (Breast Cancer, Prostate Cancer, Lung Cancer, Glioblastoma, and Melanoma), Hematological Malignancies (Lymphoma, Leukemia, and Myeloma)Regional Segmentation• North America: U.S.• Europe: Germany, France, Italy, U.K., Latvia, Armenia, Georgia, Rest-of-the-Europe (Spain, Russia, Switzerland)• Asia-Pacific – Japan, China, Rest-of-APAC (India, Australia, South Korea)Growth Drivers• Increasing Incidence of Cancer• Rising Number of Clinical Trials• Increasing Research Funding from National Cancer Institute• Increasing Adoption of Inorganic Growth Strategies in the MarketMarket Challenges• High Cost of Therapy• Lack of Therapy-Specific AssaysMarket Opportunities• Opportunities in the Emerging Economies• Drug Approvals and Strong Pipeline of Oncolytic Virus TherapiesKey Companies ProfiledAmgen, Inc., DAIICHI SANKYO COMPANY, LIMITED, DNAtrix, Genelux, Oncolytics Biotech, Inc., PsiOxus Therapeutics, RIGVIR Ltd., Shanghai Sunway Biotech Co., Ltd., SillaJen, Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Transgene sa, VCN Biosciences, ViroCure, Viralytics Ltd.Key Questions Answered in this Report:• What are the major market drivers, challenges, and opportunities in the global oncolytic virus therapies market?• What are the key development strategies being implemented by the major players in order to sustain in the competitive market? • What are the key regulatory implications in developed and developing regions for the global oncolytic virus therapies market?• How is each segment of the market expected to grow during the forecast period 2020-2030?• Who are the leading players with significant offerings to the global oncolytic virus therapies market, and what is the expected market dominance for each of these leading players?• What are the adoption trends for oncolytic virus therapies in established economies and emerging economies across the world? • What is the COVID-19 impact on the global oncolytic virus therapies market?• Which companies are anticipated to be highly disruptive in the future, and why?• What are the unmet needs that are yet to be met by the global oncolytic virus therapies with respect to the application areas?• What are the dynamics of various application areas and countries, which are impacting the global oncolytic virus therapies market?• What are the new market opportunities of various technologies that are influencing the growth of the global oncolytic virus therapies market?• How is each segment of the market expected to grow during the forecast period 2020-2030? Following are the segment types: o Commercialized Therapies o Pipeline Therapies o Type of Virus o Application o RegionMarket OverviewOncolytic virus therapies are overlapping biomedical research fields with similar therapeutic goals, which target DNA or RNA inside or outside the body. These therapies aim at modifying genetic material for the treatment of a disease. Oncolytic virotherapy is a form of gene therapy that used nature’s material (virus) to find and destroy malignant cells. Oncolytic virus therapy is “a novel approach to treat, cure, or ultimately prevent disease by changing the expression of a person’s genes”. Oncolytic virotherapy is a form of gene therapy that used nature’s material (virus) to find and destroy malignant cells.Our healthcare experts have found oncolytic virus therapies to be one of the most rapidly evolving technologies, and the global market is predicted to grow at a CAGR of 26.28% over the forecast period 2020-2030.Factors fueling the growth of the market include prevalence of cancer, rising number of clinical trials, boosting research funding, and adoption of inorganic growth. Despite rapid advanced industry growth, there are several key issues that need to be addressed to facilitate future growth such as the relatively high total costs of therapies and lacking therapy-specific assay. Further, some of the opportunities such as clinical pipeline of therapies provide growth to the market.Within the research report, the market has been segmented on the basis of commercialized therapies, pipeline therapies, type of virus, application, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.Competitive LandscapeThe exponential rise in the cases of cancer on the global level has created a buzz among companies to invest in the therapeutics of advanced technologies. Due to a large number of pipeline therapies and intense market penetration, oncolytic virus therapies have been pioneers in the therapeutic field and have significant competitors in this market.Based on region, North America held the largest share in 2020, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, Europe and the Asia-Pacific are anticipated to grow at the fastest CAGR during the forecast period.
Countries Covered :
North America U.S.Europe U.K. Latvia Georgia Armenia Germany France Italy Rest-of-EuropeAsia-Pacific China Japan Rest-of-APAC
Keywords :
Oncolytic Virus Therapies, Solid Tumor, Hematological Malignancies, Cancer Immunotherapy, Oncolytic Virus Therapies Market, Oncolytic Virus Therapies Report, Oncolytic Virus Therapies Industry, Oncolytic Virus Therapies Market Forecast, Oncolytic Virus Therapies Trends, Oncolytic Virus Therapies Products, Oncolytic Virus Therapies Applications, Oncolytic Virus Therapies Technology, Oncolytic Virus Therapies Companies, Oncolytic Virus Therapies Market Analysis, Oncolytic Virus Therapies Industry Analysis, What is Oncolytic Virus Therapies Market, What are Oncolytic Virus Therapies Market, Oncolytic Virus Therapies Market by Commercialized Therapies, Oncolytic Virus Therapies Market by Pipeline Therapies, Oncolytic Virus Therapies Market by Type of Virus, Oncolytic Virus Therapies Market by Application, Oncolytic Virus Therapies Market by Region, North America Oncolytic Virus Therapies Market, Europe Oncolytic Virus Therapies Market, Asia-Pacific Oncolytic Virus Therapies Market
Press Release :
The premium market intelligence report published by BIS Research on the title Global Oncolytic Virus Therapies Market highlights that the market is projected to reach $962.0 million by 2030. The study also highlights that the market is set to witness a CAGR of 26.28% during the forecast period 2020-2030. The global oncolytic virus therapies market is expected to grow at a double-digit compound annual growth rate in the forecast period 2020-2030, aided primarily by the impressive growth in the underlying services market.The study defines the impact of cancer on a large section of the world’s population. There were around more than 19 million new cancer cases in 2020 around the globe. As the World Health Organization states, the global healthcare expenditure is on course to be an exorbitant $8.5 trillion in 2020, owing to an increasing economic burden of chronic diseases, which is estimated to constitute almost 43% of the global economic burden. Thus, the soaring demand for better treatment outcomes is leading to an ascending need for preventive, precise healthcare and tailored medication. Oncolytic virus therapy is “a novel approach to treat, cure, or ultimately prevent disease by changing the expression of a person’s genes”. These therapies repair, deactivate, or replace dysfunctional genes that cause diseases with the aim of establishing the normal functioning of the body. Around 4,000 diseases have been linked to gene disorders, which affect millions of people across the globe. The development of oncolytic virus therapies represents a new frontier in science with the potential to help many patients. Although the field of gene therapy has experienced significant setbacks and limited success, it is still one of the most promising and active research fields in medicine.The comprehensive study covers the following:• Market numbers on micro-segments that are influencing the market? • More than 70 pipeline products present in the market • Market share analysis for more than 15 companies • Application preference data for solid tumors and hematological malignancies• Detailed global and regional market share analysis including the scrutiny of more than 15 countries?? • Study of data of more than 30 companies Who should buy this report?• Oncolytic virus therapies manufacturers, who are planning to invest in one of the large emerging markets• Companies involved in drugs development from vector-based therapies• Companies in the services market such as contract research organization• Companies involved in developing bioinformatics tools for oncology data analysis, visualization, sharing, and storageTo gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include commercialized therapies, pipeline therapies, type of virus, application, and region. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.The premium market intelligence by BIS Research, additionally, throws a spotlight on the opportunities existing in the market, including the high scope for adoption of oncolytic virus therapies in emerging nations, increased use of therapies, and provide solutions for one of the chronic diseases.The application and pricing analysis of the global market includes data analysis on the satisfaction level of different commercialized therapies. The study is majorly centered on the sub-segments and micro-segments of the different commercialized products in the market.To emphasize the dominance of the North America segment in the regional segmentation of global oncolytic virus therapies market in 2020 and 2030, Nitish Kumar Singh, Principal Analyst – BIS Research, states, "North America is the leading contributor in the global oncolytic virus therapies market and contributed approximately 65.56% to the global market value in 2019. This region is anticipated to grow at a CAGR of 26.21% during the forecast period 2020-2030 and continue dominating the global market in 2030. However, the Europe region is expected to grow at an impressive CAGR of 29.69% during the forecast period from 2020 to 2030.”Key insights are drawn from in-depth interviews with the key opinion leaders of more than 15 leading companies, market participants, and vendors. The key players profiled in the report include Amgen, Inc., DAIICHI SANKYO COMPANY, LIMITED, DNAtrix, Genelux, Oncolytics Biotech, Inc., PsiOxus Therapeutics, RIGVIR Ltd., Shanghai Sunway Biotech Co., Ltd., SillaJen, Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Transgene sa, VCN Biosciences, ViroCure, and Viralytics Ltd.The study also offers strategic recommendations that can help organizations in tracking various products, trends, and applications that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.How can market intelligence on oncolytic virus therapies add value to an organization’s decision-making process?• Aid in drug development • Help in targeting a segment for launching a new drug • Offer detailed information on the future perspective of the emerging as well as established players• Offer go-to market strategies for the different source type• Support in diversifying the product portfolio based on risk and progression of application • Help in analyzing technological substitutes and compare the specification• Offer tailor-made solutions based on the throughput of different consumers• Aid in understanding the technology requirement• Assist in exploring the newer application• Support in analyzing the competitors’ funding scenario• Support in understanding the involvement of government health organizations such as the National Institute of Health (NIH)• Aid in understanding the new trends in the industryInsightful Questions Covered to Enable Companies take Strategic Decisions• What are the major market drivers, challenges, and opportunities in the global oncolytic virus therapies market?• What are the key development strategies being implemented by the major players in order to sustain in the competitive market? • What are the key regulatory implications in developed and developing regions for the global oncolytic virus therapies market?• How is each segment of the market expected to grow during the forecast period 2020-2030?• Who are the leading players with significant offerings to the global oncolytic virus therapies market, and what is the expected market dominance for each of these leading players?• What are the adoption trends for oncolytic virus therapies in established economies and emerging economies across the world? • What is the COVID-19 impact on the global oncolytic virus therapies market?• Which companies are anticipated to be highly disruptive in the future, and why?• What are the unmet needs that are yet to be met by the global oncolytic virus therapies with respect to the application areas?• What are the dynamics of various application areas and countries impacting the global oncolytic virus therapies market?• What are the new market opportunities of various technologies that are influencing the growth of the global oncolytic virus therapies market?• How is each segment of the market expected to grow during the forecast period 2020-2030? Following are the segment types: • Commercialized Therapies • Pipeline Therapies • Type of Virus • Application • Region
Companies Mentioned :
Amgen Inc.DAIICHI SANKYO COMPANY, LIMITEDDNAtrixGeneluxOncolytics Biotech, Inc.PsiOxus TherapeuticsRIGVIR Ltd.Shanghai Sunway Biotech Co., Ltd.,SillaJen, Inc.Sorrento Therapeutics, Inc.Takara Bio Inc.Transgene saVCNBiosciencesViroCureViralytics Ltd. (Merck & Co., Inc.)
Press Release :
The premium market intelligence report published by BIS Research on the title Global Oncolytic Virus Therapies Market highlights that the market is projected to reach $962.0 million by 2030. The study also highlights that the market is set to witness a CAGR of 26.28% during the forecast period 2020-2030. The global oncolytic virus therapies market is expected to grow at a double-digit compound annual growth rate in the forecast period 2020-2030, aided primarily by the impressive growth in the underlying services market.The study defines the impact of cancer on a large section of the world’s population. There were around more than 19 million new cancer cases in 2020 around the globe. As the World Health Organization states, the global healthcare expenditure is on course to be an exorbitant $8.5 trillion in 2020, owing to an increasing economic burden of chronic diseases, which is estimated to constitute almost 43% of the global economic burden. Thus, the soaring demand for better treatment outcomes is leading to an ascending need for preventive, precise healthcare and tailored medication. Oncolytic virus therapy is “a novel approach to treat, cure, or ultimately prevent disease by changing the expression of a person’s genes”. These therapies repair, deactivate, or replace dysfunctional genes that cause diseases with the aim of establishing the normal functioning of the body. Around 4,000 diseases have been linked to gene disorders, which affect millions of people across the globe. The development of oncolytic virus therapies represents a new frontier in science with the potential to help many patients. Although the field of gene therapy has experienced significant setbacks and limited success, it is still one of the most promising and active research fields in medicine.The comprehensive study covers the following:• Market numbers on micro-segments that are influencing the market? • More than 70 pipeline products present in the market • Market share analysis for more than 15 companies • Application preference data for solid tumors and hematological malignancies• Detailed global and regional market share analysis including the scrutiny of more than 15 countries?? • Study of data of more than 30 companies Who should buy this report?• Oncolytic virus therapies manufacturers, who are planning to invest in one of the large emerging markets• Companies involved in drugs development from vector-based therapies• Companies in the services market such as contract research organization• Companies involved in developing bioinformatics tools for oncology data analysis, visualization, sharing, and storageTo gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include commercialized therapies, pipeline therapies, type of virus, application, and region. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.The premium market intelligence by BIS Research, additionally, throws a spotlight on the opportunities existing in the market, including the high scope for adoption of oncolytic virus therapies in emerging nations, increased use of therapies, and provide solutions for one of the chronic diseases.The application and pricing analysis of the global market includes data analysis on the satisfaction level of different commercialized therapies. The study is majorly centered on the sub-segments and micro-segments of the different commercialized products in the market.To emphasize the dominance of the North America segment in the regional segmentation of global oncolytic virus therapies market in 2020 and 2030, Nitish Kumar Singh, Principal Analyst – BIS Research, states, "North America is the leading contributor in the global oncolytic virus therapies market and contributed approximately 65.56% to the global market value in 2019. This region is anticipated to grow at a CAGR of 26.21% during the forecast period 2020-2030 and continue dominating the global market in 2030. However, the Europe region is expected to grow at an impressive CAGR of 29.69% during the forecast period from 2020 to 2030.”Key insights are drawn from in-depth interviews with the key opinion leaders of more than 15 leading companies, market participants, and vendors. The key players profiled in the report include Amgen, Inc., DAIICHI SANKYO COMPANY, LIMITED, DNAtrix, Genelux, Oncolytics Biotech, Inc., PsiOxus Therapeutics, RIGVIR Ltd., Shanghai Sunway Biotech Co., Ltd., SillaJen, Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Transgene sa, VCN Biosciences, ViroCure, and Viralytics Ltd.The study also offers strategic recommendations that can help organizations in tracking various products, trends, and applications that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.How can market intelligence on oncolytic virus therapies add value to an organization’s decision-making process?• Aid in drug development • Help in targeting a segment for launching a new drug • Offer detailed information on the future perspective of the emerging as well as established players• Offer go-to market strategies for the different source type• Support in diversifying the product portfolio based on risk and progression of application • Help in analyzing technological substitutes and compare the specification• Offer tailor-made solutions based on the throughput of different consumers• Aid in understanding the technology requirement• Assist in exploring the newer application• Support in analyzing the competitors’ funding scenario• Support in understanding the involvement of government health organizations such as the National Institute of Health (NIH)• Aid in understanding the new trends in the industryInsightful Questions Covered to Enable Companies take Strategic Decisions• What are the major market drivers, challenges, and opportunities in the global oncolytic virus therapies market?• What are the key development strategies being implemented by the major players in order to sustain in the competitive market? • What are the key regulatory implications in developed and developing regions for the global oncolytic virus therapies market?• How is each segment of the market expected to grow during the forecast period 2020-2030?• Who are the leading players with significant offerings to the global oncolytic virus therapies market, and what is the expected market dominance for each of these leading players?• What are the adoption trends for oncolytic virus therapies in established economies and emerging economies across the world? • What is the COVID-19 impact on the global oncolytic virus therapies market?• Which companies are anticipated to be highly disruptive in the future, and why?• What are the unmet needs that are yet to be met by the global oncolytic virus therapies with respect to the application areas?• What are the dynamics of various application areas and countries impacting the global oncolytic virus therapies market?• What are the new market opportunities of various technologies that are influencing the growth of the global oncolytic virus therapies market?• How is each segment of the market expected to grow during the forecast period 2020-2030? Following are the segment types: • Commercialized Therapies • Pipeline Therapies • Type of Virus • Application • Region
Headline :
Global Oncolytic Virus Therapies Market to Reach $962.0 Million by 2030
Table of Contents :
Executive Summary 1 Product Definition1.1 Inclusion and Exclusion2 Market Scope2.1 Scope of Work2.2 Key Questions Answered in the Report3 Research Methodology3.1 Global Oncolytic Virus Therapies Market: Research Methodology3.2 Primary Data Sources3.3 Secondary Data Sources3.4 Market Estimation Model3.5 Criteria for Company Profiling4 Market Overview4.1 Market Definition4.2 Importance of Oncolytic Virus Therapies in Cancer Treatment4.3 Market Size and Growth Potential, $Million, 2019-20304.4 COVID-19 Impact on the Global Oncolytic Virus Therapies Market5 Industry Insights5.1 Overview5.2 Regulatory Scenario5.3 Legal Requirements and Framework in the U.S5.3.1 Clinical Trial Authorization5.3.2 U.S. FDA Guidelines for BLA Submission5.4 Legal Requirements and Framework in Europe5.4.1 EMA Biologics License Application Process5.4.2 Centralized Procedure5.4.3 Decentralized Procedure5.4.4 Mutual-Recognition Procedure5.5 Legal Requirements and Framework in Asia-Pacific5.5.1 China5.5.2 Japan5.6 Expedited Regulatory Designations Around the World5.7 Reimbursement Scenario5.8 Patent Analysis5.8.1 Patent Filing Trend6 Market Dynamics6.1 Overview6.2 Impact Analysis6.3 Market Drivers6.3.1 Increasing Incidence of Cancer6.3.2 Rising Number of Clinical Trials6.3.3 Increasing Research Funding from National Cancer Institute6.3.4 Increasing Adoption of Inorganic Growth Strategies in the Market6.4 Market Restrains6.4.1 High Cost of Therapy6.4.2 Lack of Therapy-Specific Assays6.5 Market Opportunities6.5.1 Opportunities in the Emerging Economies6.5.2 Drug Approvals and Strong Pipeline of Oncolytic Virus Therapies7 Competitive Landscape7.1 Synergistic Activities7.2 Business Expansion Activities and Others7.3 Product Launches and Product Updates7.4 Mergers and Acquisitions7.5 Market Share Analysis7.6 Growth Share Analysis7.6.1 Growth Share Analysis (by Commercialized Therapy)8 Oncolytic Virus Therapies: Epidemiology Analysis9 Global Oncolytic Virus Therapies Market (by Commercialized Therapies), $Million, 2019-20309.1 Overview9.2 Imlygic9.3 Oncorine9.4 RIGVIR10 Global Oncolytic Virus Therapies Market (by Pipeline Therapies), $Million, 2019-203010.1 Overview10.2 Phase I10.3 Phase II10.4 Phase III10.5 Phase IV11 Global Oncolytic Virus Therapies Market (by Type of Virus), $Million, 2019-203011.1 Overview11.2 Genetically Engineered Oncolytic Virus11.2.1 Herpes Simplex Virus (HSV)11.2.2 Adenovirus11.2.3 Vaccinia Virus11.3 Oncolytic Wild-Type Virus11.3.1 Reovirus (Respiratory Enteric Orphan Virus)11.3.2 Newcastle Disease Virus (NDV)11.3.3 Vesicular Stomatitis Virus (VSV)12 Global Oncolytic Virus Therapies Market (by Application), $Million, 2019-203012.1 Overview12.2 Solid Tumor12.2.1 Breast Cancer12.2.2 Prostate Cancer12.2.3 Lung Cancer12.2.4 Glioblastoma12.2.5 Melanoma12.2.6 Other Applications12.3 Hematological Malignancies12.3.1 Lymphoma12.3.2 Leukemia12.3.3 Myeloma13 Global Oncolytic Virus Therapies Market (by Region), $Million, 2019-203013.1 Overview13.2 North America13.2.1 U.S.13.3 Europe13.3.1 U.K.13.3.2 Latvia13.3.3 Georgia13.3.4 Armenia13.3.5 Germany13.3.6 France13.3.7 Italy13.3.8 Rest-of-Europe13.4 Asia-Pacific13.4.1 China13.4.2 Japan13.4.3 Rest-of-APAC14 Company Profiles14.1 Overview14.2 Amgen Inc.14.2.1 Company Overview14.2.2 Role of Amgen Inc. in the Global Oncolytic Virus Therapies Market14.2.3 Financials14.2.4 Key Insights about Financial Health of the Company14.2.5 SWOT Analysis14.3 DAIICHI SANKYO COMPANY, LIMITED14.3.1 Company Overview14.3.2 Role of DAIICHI SANKYO COMPANY, LIMITED in the Global Oncolytic Virus Therapies Market14.3.3 Financials14.3.4 Key Insights About Financial Health of the Company14.3.5 SWOT Analysis14.4 DNAtrix14.4.1 Company Overview14.4.2 Role of DNAtrix in the Global Oncolytic Virus Therapies Market14.4.3 SWOT Analysis14.5 Genelux14.5.1 Company Overview14.5.2 Role of Genelux in the Global Oncolytic Virus Therapies Market14.5.3 SWOT Analysis14.6 Oncolytics Biotech, Inc.14.6.1 Company Overview14.6.2 Role of Oncolytics Biotech, Inc. in the Global Oncolytic Virus Therapies Market14.6.3 Financials14.6.4 SWOT Analysis14.7 PsiOxus Therapeutics14.7.1 Company Overview14.7.2 Role of PsiOxus Therapeutics in the Global Oncolytic Virus Therapies Market14.7.3 SWOT Analysis14.8 RIGVIR Ltd.14.8.1 Company Overview14.8.2 Role of RIGVIR Ltd. in the Global Oncolytic Virus Therapies Market14.8.3 SWOT Analysis14.9 Shanghai Sunway Biotech Co., Ltd.,14.9.1 Company Overview14.9.2 Role of Shanghai Sunway Biotech Co., Ltd., in the Global Oncolytic Virus Therapies Market14.9.3 SWOT Analysis14.1 SillaJen, Inc.14.10.1 Company Overview14.10.2 Role of SillaJen, Inc. in the Global Oncolytic Virus Therapies Market14.10.3 SWOT Analysis14.11 Sorrento Therapeutics, Inc.14.11.1 Company Overview14.11.2 Role of Sorrento Therapeutics, Inc. in Global Oncolytic Virus Therapies Market14.11.3 Financials14.11.4 Key Insights About Financial Health of the Company14.11.5 SWOT Analysis14.12 Takara Bio Inc.14.12.1 Company Overview14.12.2 Role of Takara Bio Inc. in the Global Oncolytic Virus Therapies Market14.12.3 Financials14.12.4 Key Insights About Financial Health of the Company14.12.5 SWOT Analysis14.13 Transgene sa14.13.1 Company Overview14.13.2 Role of Transgene sa in the Global Oncolytic Virus Therapies Market14.13.3 Financials14.13.4 SWOT Analysis14.14 VCNBiosciences14.14.1 Company Overview14.14.2 Role of VCNBiosciences in the Global Oncolytic Virus Therapies Market14.14.3 SWOT Analysis14.15 ViroCure14.15.1 Company Overview14.15.2 Role of ViroCure in the Global Oncolytic Virus Therapies Market14.15.3 SWOT Analysis14.16 Viralytics Ltd. (Merck & Co., Inc.)14.16.1 Company Overview14.16.2 Role of Merck & Co., Inc. in the Global Oncolytic Virus Therapies Market14.16.3 Financials14.16.4 Key Insights About Financial Health of the Company14.16.5 SWOT AnalysisList of Tables Table 5.1: Regulatory Scenario Across the WorldTable 5.2: Expedited Regulatory Designations Around the WorldTable 5.3: Key Market Access Landscape (by Country), January 2019Table 9.1: Commercialized TherapiesTable 10.1: Key Oncolytic Virus Therapies in Clinical Development Phase I, 2020Table 10.2: Key Oncolytic Virus Therapies in Clinical Development Phase II, 2020Table 10.3: Key Oncolytic Virus Therapies in Clinical Development Phase III, 2020Table 11.1: Key Herpes Simplex Virus (HSV)-Based Oncolytic TherapiesTable 11.2: Key Adenovirus-Based Oncolytic TherapiesTable 11.3: Key Vaccinia Virus-Based Oncolytic TherapiesTable 11.4: Key Reovirus-Based Oncolytic TherapiesTable 13.1: Rest-of-APAC - Pipeline DrugsList of Figures Figure 1: NCI Fiscal Budget Year on Year, 2013-2018Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Oncolytic Virus Therapies MarketFigure 3: Global Oncolytic Virus Therapies Market (by Application), $Million, 2019 Vs. 2030Figure 4: Global Oncolytic Virus Therapies Market (by Type of Virus), $Million, 2019 vs. 2030Figure 5: Global Oncolytic Virus Therapies Market Snapshot, $Million, 2019 and 2030Figure 2.1: Global Oncolytic Virus Therapies Market SegmentationFigure 3.1: Global Oncolytic Virus Therapies Market Research MethodologyFigure 3.2: Primary Research MethodologyFigure 3.3: Bottom-Up Approach (Segment-Wise Analysis)Figure 3.4: Top-Down Approach (Segment-Wise Analysis)Figure 4.1: Global Oncolytic Virus Therapies Market, $Million, 2019-2030Figure 4.2: Global Oncolytic Virus Therapies Market: COVID-19 ImpactFigure 5.1: Clinical Trial Authorization for Oncolytic Virus TherapiesFigure 5.2: Steps for Obtaining Marketing AuthorizationFigure 5.3: U.S. FDA Expedited Review ProgramsFigure 5.4: Regulatory Strategy for Oncolytic Virus Therapies in the U.S.Figure 5.5: U.S.FDA Review TimelineFigure 5.6: Regulatory Strategy for Oncolytic Virus Therapies in EuropeFigure 5.7: EMA Review TimelineFigure 5.9: Overview of PMDA and MLHW Drug Approval Process in JapanFigure 5.10: Global Oncolytic Virus Therapies Market: Patent Analysis (by Country and Year), January 2015-March 2021Figure 6.1: Impact AnalysisFigure 6.2: Cancer Cases Projection, 2016-2020Figure 6.3: Number of Active and Completed Clinical Trials for Gene Therapy (by Start Date), 2015-2019Figure 6.4: SBIR and STTR Grants and Contract Funding, 2008-2018Figure 6.5: NCI Fiscal Budget Year-on-Year, 2013-2018Figure 6.6: Synergistic Activities, 2018-2020Figure 7.1: Share of Key Developments and Strategies, January 2018-March 2021Figure 7.2: Synergistic Activities Share (by Company), January 2018-March 2021Figure 7.3: Business Expansion Activities Share (by Company), January 2018-March 2021Figure 7.4: Number of Product Launches (by Company), January 2018-March 2021Figure 7.5: Mergers and Acquisitions, January 2018-March 2021Figure 7.6: Market Share Analysis for Global Oncolytic Virus Therapies Market, (by Application), $Million, 2020Figure 7.7: Growth Share Analysis for Global Oncolytic Virus Therapies Market (by Commercialized Therapy), 2019-2020Figure 8.1: Type of CancerFigure 8.2: Global Estimated Percent of New Cancer Cases (by Sex), 2030Figure 8.3: Expected Cancer Cases in the World (by Country), 2030Figure 8.4: Relative Number of Expected New Cancer Cases (by Country), 2030Figure 9.1: Global Oncolytic Virus Therapies Market (Imlygic), $Million, 2019-2030Figure 9.2: Global Oncolytic Virus Therapies Market (Oncorine), $Million, 2019-2030Figure 9.3: Global Oncolytic Virus Therapies Market (RIGVIR), $Million, 2019-2030Figure 10.1: Oncolytic Virus Gene Therapy Medicines in Development (by Disease), 2019Figure 11.1: Global Oncolytic Virus Therapies Market (by Type of Virus), $Million, 2019-2030Figure 11.2: Global Oncolytic Virus Therapies Market (by Genetically Engineered Oncolytic Virus), $Million, 2019 and 2030Figure 11.3: Global Oncolytic Virus Therapies Market (Herpes Simplex Virus), $Million, 2019-2030Figure 11.4: Global Oncolytic Virus Therapies Market (Adenovirus), $Million, 2019-2030Figure 11.5: Global Oncolytic Virus Therapies Market (Vaccinia Virus), $Million, 2019-2030Figure 11.6: Global Oncolytic Virus Therapies Market (by Oncolytic Wild-Type Virus), $Million, 2019 and 2030Figure 11.7: Global Oncolytic Virus Therapies Market (Reovirus), $Million, 2019-2030Figure 11.8: Global Oncolytic Virus Therapies Market (Newcastle Disease Virus), $Million, 2019-2030Figure 11.9: Global Oncolytic Virus Therapies Market (Vesicular Stomatitis Virus), $Million, 2019-2030Figure 12.1: Global Oncolytic Virus Therapies Market (by Application), $Million, 2019-2030Figure 12.2: Global Oncolytic Virus Therapies Market (by Solid Tumor), $Million, 2019 and 2030Figure 12.3: Global Oncolytic Virus Therapies Market (Breast Cancer), $Million, 2019-2030Figure 12.4: Global Oncolytic Virus Therapies Market (Prostate Cancer), $Million, 2019-2030Figure 12.5: Global Oncolytic Virus Therapies Market (Lung Cancer), $Million, 2019-2030Figure 12.6: Global Oncolytic Virus Therapies Market (Glioblastoma), $Million, 2019-2030Figure 12.7: Global Oncolytic Virus Therapies Market (Melanoma), $Million, 2019-2030Figure 12.8: Global Oncolytic Virus Therapies Market (Other Applications), $Million, 2019-2030Figure 12.9: Global Oncolytic Virus Therapies Market (by Haematological Malignancies), $Million, 2019 and 2030Figure 12.10: Global Oncolytic Virus Therapies Market (Lymphoma), $Million, 2019-2030Figure 12.11: Global Oncolytic Virus Therapies Market (Leukemia), $Million, 2019-2030Figure 12.12: Global Oncolytic Virus Therapies Market (Myeloma), $Million, 2019-2030Figure 13.1: Global Oncolytic Virus Therapies Market (by Region), 2019-2030Figure 13.2: Global Oncolytic Virus Therapies Market (by Region), $Million, 2019-2030Figure 13.3: Global Oncolytic Virus Therapies Market Share (by Region), $Million, 2019Figure 13.4: Global Oncolytic Virus Therapies Market Share (by Region), $Million, 2030Figure 13.5: North America Oncolytic Virus Therapies Market, $Million, 2019-2030Figure 13.6: North America: Market DynamicsFigure 13.7: U.S. Oncolytic Virus Therapies Market, $Million, 2019-2030Figure 13.8: Europe Oncolytic Virus Therapies Market, $Million, 2019-2030Figure 13.9: Europe: Market DynamicsFigure 13.10: Europe Oncolytic Virus Therapies Market (by Country), $Million, 2019-2030Figure 13.11: U.K. Oncolytic Virus Therapies Market, $Million, 2019-2030Figure 13.12: Latvia Oncolytic Virus Therapies Market, $Million, 2019-2030Figure 13.13: Georgia Oncolytic Virus Therapies Market, $Million, 2019-2030Figure 13.14: Armenia Oncolytic Virus Therapies Market, $Million, 2019-2030Figure 13.15: Germany Oncolytic Virus Therapies Market, $Million, 2019-2030Figure 13.16: France Oncolytic Virus Therapies Market, $Million, 2019-2030Figure 13.17: Italy Oncolytic Virus Therapies Market, $Million, 2019-2030Figure 13.18: Rest-of-Europe Oncolytic Virus Therapies Market, $Million, 2019-2030Figure 13.19: Asia-Pacific Oncolytic Virus Therapies Market, $Million, 2019-2030Figure 13.20: APAC: Market DynamicsFigure 13.21: APAC Oncolytic Virus Therapies Market (by Country), $Million, 2019-2030Figure 13.22: China Oncolytic Virus Therapies Market, $Million, 2019-2030Figure 13.23: Japan Oncolytic Virus Therapies Market, $Million, 2019-2030Figure 13.24: RoAPAC Oncolytic Virus Therapies Market, $Million, 2019-2030Figure 14.1: Total Number of Companies ProfiledFigure 14.2: Amgen Inc.: Product PortfolioFigure 14.3: Amgen Inc.: Overall Financials, $Million, 2018-2020Figure 14.4: Amgen Inc.: Revenue (by Region), $Million, 2018-2020Figure 14.5: Amgen Inc. R&D Expenditure, $Billion, 2018-2020Figure 14.6: Amgen Inc.: SWOT AnalysisFigure 14.7: DAIICHI SANKYO COMPANY, LIMITED: Product PortfolioFigure 14.8: DAIICHI SANKYO COMPANY, LIMITED: Overall Financials, $Billion, 2017-2019Figure 14.9: Amgen Inc. R&D Expenditure, $Billion, 2017-2019Figure 14.10: DAIICHI SANKYO COMPANY, LIMITED: SWOT AnalysisFigure 14.11: DNAtrix: Product PortfolioFigure 14.12: DNAtrix: SWOT AnalysisFigure 14.13: Genelux: Product PortfolioFigure 14.14: Genelux: SWOT AnalysisFigure 14.15: Oncolytics Biotech, Inc.: Product PortfolioFigure 14.16: Oncolytics Biotech, Inc.: SWOT AnalysisFigure 14.17: PsiOxus Therapeutics: Pipeline Product PortfolioFigure 14.18: PsiOxus Therapeutics: SWOT AnalysisFigure 14.19: RIGVIR Ltd.: Overall Service PortfolioFigure 14.20: RIGVIR Ltd.: SWOT AnalysisFigure 14.21: Product Portfolio: Shanghai Sunway Biotech Co., Ltd.,Figure 14.22: Shanghai Sunway Biotech Co., Ltd.: SWOT AnalysisFigure 14.23: SillaJen, Inc.: Product PortfolioFigure 14.24: SillaJen, Inc.: SWOT AnalysisFigure 14.25: Sorrento Therapeutics, Inc.: Product PortfolioFigure 14.26: Sorrento Therapeutics, Inc.: Overall Financials, 2017-2019Figure 14.27: Sorrento Therapeutics, Inc. R&D Expenditure, $Million, 2017-2019Figure 14.28: Sorrento Therapeutics, Inc.: SWOT AnalysisFigure 14.29: Takara Bio Inc.: Product PortfolioFigure 14.30: Takara Bio Inc.: Overall Financials, 2017-2019Figure 14.31: Takara Bio Inc.: Revenue (by Segment), $Million, 2017-2019Figure 14.32: Takara Bio Inc.: Revenue (by Region), $Million, 2017-2019Figure 14.33: Takara Bio Inc.: R&D Expenditure, 2017-2019Figure 14.34: Takara Bio Inc.: SWOT AnalysisFigure 14.35: Transgene sa: Product PortfolioFigure 14.36: Transgene sa: Overall Financials, $Million, 2017-2019Figure 14.37: Transgene sa: SWOT AnalysisFigure 14.38: VCNBiosciences: Pipeline Product PortfolioFigure 14.39: VCNBiosciences: SWOT AnalysisFigure 14.40: ViroCure: Product PortfolioFigure 14.41: ViroCure: SWOT AnalysisFigure 14.42: Viralytics Ltd., (Merck & Co., Inc.): Product PortfolioFigure 14.43: Merck & Co., Inc.: Overall Financials, $Million, 2018-2020Figure 14.44: Merck & Co., Inc.: Revenue (by Segment), $Million, 2018-2020Figure 14.45: Merck & Co., Inc.: Revenue (by Region), $Million, 2018-2020Figure 14.46: Merck & Co., Inc.: R&D Expenditure, $Million, 2018-2020Figure 14.47: Merck & Co., Inc.: SWOT Analysis